TICKERNERD
Menu
SLGLSLGLHealthcare · Biotechnology

SLGL Stock Forecast: Sol-Gel Technologies Ltd. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$78
−0.48% on the day

The 4 Wall Street analysts covering Sol-Gel Technologies Ltd. hold a median 12-month price target of $195 — +149.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 45 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$254.1M
Ticker Nerd rank
45 / 100
Median analyst target
$195
Analysts covering
4
Total return, dividends reinvested
1W
−7.8%
1M
−12.9%
YTD
+85.4%
1Y
+202.8%
From 52W high
−20.3%
From 52W low
+272.0%
$21
$98
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SLGL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Sol-Gel Technologies Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
45 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
86
Revisions
69
Size
65
Issuance
52
Volatility
42
Value
38
Accruals
37
Quality
28
Growth
19

Momentum (86): The shares have been drifting up relative to others.

Growth (19): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SLGL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SLGL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$50$100$150$200$250$300$350Oct 25Jan 26Apr 26Jul 26SLGLHigh $285Median $195Low $110

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $110Median $195High $285

The green dot is the last close — the median target sits +149.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 July 2026HC Wainwright & Co.ReiteratesBuy$110
24 June 2026MizuhoInitiatesOutperform$285
24 June 2026MizuhoInitiatesOutperform—
20 Jan 2026HC Wainwright & Co.MaintainsBuy—
22 Dec 2025HC Wainwright & Co.ReiteratesBuy—
27 Oct 2025HC Wainwright & Co.MaintainsBuy—
19 Aug 2024Raymond JamesDowngradeOutperform—
22 May 2024HC Wainwright & Co.ReiteratesBuy—
20 May 2024HC Wainwright & Co.MaintainsBuy—
13 Nov 2023HC Wainwright & Co.MaintainsBuy—
14 Aug 2023HC Wainwright & Co.MaintainsBuy—
11 Aug 2023Raymond JamesMaintainsStrong Buy—
24 July 2023HC Wainwright & Co.ReiteratesBuy—
19 July 2023Raymond JamesMaintainsStrong Buy—
5 June 2023HC Wainwright & Co.ReiteratesBuy—
12 Apr 2023HC Wainwright & Co.ReiteratesBuy—
14 Mar 2023Raymond JamesMaintainsStrong Buy—
1 Feb 2023HC Wainwright & Co.ReiteratesBuy—
14 Nov 2022HC Wainwright & Co.MaintainsBuy—
11 Nov 2022Raymond JamesMaintainsStrong Buy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SLGL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

SLGL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Sol-Gel Technologies Ltd. (SLGL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−35.2×

Cheaper than 97% of US stocks

Price / sales
141.6×

Cheaper than 3% of US stocks

Price / book
5.3×

Cheaper than 11% of US stocks

EV / EBITDA
−11.7×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
−96.6%

Higher than 2% of US stocks

Earnings growth (YoY)
−89.5%

Higher than 3% of US stocks

Gross margin
—
Operating margin
−704.2%

Higher than 6% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−40.9%

Higher than 24% of US stocks

Return on assets
−23.9%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

SLGL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SLGLSol-Gel Technologies Ltd.$254.1M
45
NAGENiagen Bioscience, Inc.$254.0M
54
PYXSPyxis Oncology, Inc.$256.9M
80
ALECAlector, Inc.$257.6M
42
MGNXMacroGenics, Inc.$260.6M
67
CGENCompugen Ltd.$247.3M
82
GLSIGreenwich LifeSciences, Inc.$244.7M
41

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Sol-Gel Technologies Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SLGL news & analysis

Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

GlobeNewsWire · 20 Aug 2026neutral

Sol-Gel Technologies announced its financial results for the second quarter ended June 30, 2026, and provided a corporate update. The announcement was made on August 20, 2026, from the company's headquarters in Ness Ziona, Israel.

Why it matters — A SLGL watcher would care because the quarterly financial results and corporate update provide insight into the company's recent performance and strategic direction.

FAQ

Frequently asked questions about SLGL stock

What is the SLGL stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Sol-Gel Technologies Ltd. have a median 12-month price target of $195, with estimates ranging from $110 to $285. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SLGL stock a buy right now?

Of the 4 analysts covering Sol-Gel Technologies Ltd., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sol-Gel Technologies Ltd. 45 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SLGL?

As at 22 Aug 2026, Sol-Gel Technologies Ltd. ranks 45 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (86 of 100).

Will SLGL stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +149.6% from the last close, and Ticker Nerd's factor model ranks Sol-Gel Technologies Ltd. 45 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SLGL stock forecast for 2030?

No analyst covering Sol-Gel Technologies Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SLGL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $110 to $285 over the next 12 months.

How has SLGL stock performed over the past year?

Sol-Gel Technologies Ltd. returned +202.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Sol-Gel Technologies Ltd. do?

Sol-Gel Technologies Ltd. is a pharmaceutical company specializing in dermatological treatments utilizing its proprietary aerosol-based, drug-delivery platform.

What is the latest news on SLGL?

The most recent item we track (GlobeNewsWire, 20 Aug 2026): "Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates". Sol-Gel Technologies announced its financial results for the second quarter ended June 30, 2026, and provided a corporate update. The announcement was made on August 20, 2026, from the company's headquarters in Ness Ziona, Israel.

Company

About Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd. is a pharmaceutical company specializing in dermatological treatments utilizing its proprietary aerosol-based, drug-delivery platform. Founded in 1997 and headquartered in Israel, Sol-Gel develops topical dermatology products to address common skin conditions such as acne and rosacea. The company's innovative approach leverages nanotechnology to create microencapsulation systems that improve drug efficacy, stability, and patient experience. By focusing on these prevalent conditions, Sol-Gel plays a vital role in the pharmaceutical sector, particularly in advancing topical treatment technologies. With a commitment to research and development, Sol-Gel Technologies seeks collaborations and partnerships to further enhance its product pipeline and expand its market presence, contributing significantly to the dermatology therapeutics industry.

CEO Mr. Moshe Arkin · 28 employees · Israel · https://www.sol-gel.com